Outcomes of Veterans with FMS-like Tyrosine Kinase 3 Mutated (mFLT3) Acute Myeloid Leukemia (AML) Treated with Novel FLT3 Inhibitors (FLT3i) within the Veterans Health Administration (VHA)

Introduction AML is a heterogenous myeloid cell malignancy with mFLT3 found in ~30% of patients. Internal tandem duplication (ITD) mutated AML is associated with more aggressive disease and a poorer prognosis compared to a mFLT3 in the tyrosine kinase domain (TKD). First- and second- generation smal...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.7414-7414
Hauptverfasser:	Garcia, Eduardo, Horowitz, Amy M, Franklin, Kathleen, Mader, Michael, Kaur, Supreet
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!